HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Local Partners Key To Unlocking China’s $40bn Dietary Supplements Market

Executive Summary

Finding the right local partner and maintaining close relationships with them is how Irish iron supplement specialist Solvotrin Therapeutics is accessing China's lucrative but challenging bricks-and-mortar retail market, according to the company's COO Ronan McClafferty.

You may also be interested in...



Want A Slice Of China’s $40bn VMS Market? Learn To Navigate Alibaba’s ‘New Retail’ Ecosystem

The UK's Vitabiotics is expanding its presence in China's lucrative dietary supplements market via Alibaba Group's Tmall e-commerce platform. HBW Insight speaks exclusively to Vitabiotics' China and South Asia director, Benji Lamb, about how the firm has used local knowledge to successfully navigate the country's "new retail" phenomenon. 

2020 In Review: HBW Insight’s Five Key Takeaways For The European OTC Industry

HBW Insight extracts five key lessons from 2020, the year the coronavirus pandemic swept its way across Europe. 

Planting Seeds In China’s Burgeoning CBD Market

China holds huge potential as an emerging CBD food supplements market. HBW Insight speaks to Canadian start-up Mary Agrotechnologies, one of the few companies to hold a license to manufacture CBD in China, about the changing regulatory situation in the country, and Mary's strategy to seize this exciting opportunity. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel